Saturday 17 October 2026
Export CCEL’s income statement to Excel — free account
Cryo-Cell International Inc.
CCEL Healthcare Medical Care Facilities
Cryo-Cell International Inc.’s revenue for fiscal 2025 (year ended November 2025) was $31.6 million, down 1.31% from fiscal 2024. In the quarter to August 2026, revenue was flat, EPS grew 77.8%, free cash flow fell 58.4% and total debt fell 29.5%, each against the same quarter a year earlier.
4.42
0.77
+21.10%
Follow CCEL
| Aug '26 | May '26 | Feb '26 | Nov '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.09 | 0.92 | 0.84 | 1.02 | |
P/FCF ratio |
10.63 | 6.16 | 7.36 | 8.24 | |
P/Operating CF |
29.66 | 15.49 | 40.54 | 25.07 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.26 | 1.13 | 1.06 | 1.24 | |
EV/EBITDA |
25.19 | 27.30 | 21.01 | 20.99 | |
EV/Operating CF |
7.98 | 5.56 | 6.42 | 7.17 | |
EV/FCF |
12.33 | 7.56 | 9.26 | 10.08 | |
Quick Ratio |
0.72 | 0.63 | 0.55 | 0.51 | |
Current Ratio |
0.86 | 0.71 | 0.62 | 0.59 | |
Net Debt/EBITDA |
1.51 | 3.18 | 6.14 | (1.98) | |
Debt/Assets |
12.91% | 13.31% | 15.98% | 16.96% | |
Debt/Equity |
(0.49) | (0.46) | (0.53) | (0.56) | |
Asset Turnover |
0.50 | 0.50 | 0.50 | 0.50 | |
Operating CF/Net income |
0.90 | 3.33 | 13.84 | (0.34) | |
Capex/Depreciation |
(0.30) | (0.09) | (0.19) | (0.20) | |
Interest Coverage |
5.01 | 2.71 | 1.65 | (8.23) | |
Research and Development Expense of Revenue |
0.69% | 1.28% | 0.86% | 1.08% | |
Selling, General and Administrative Expense of Revenue |
48.30% | 59.39% | 65.23% | 69.47% | |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(1.93) | (2.35) | (2.58) | (2.14) | |
Graham Number |
3.27 | 3.88 | 4.14 | 4.01 | |
Earnings Yield |
(5.58%) | (8.57%) | (10.19%) | (7.79%) | |
Free Cash Flow Yield |
9.40% | 16.23% | 13.58% | 12.13% | |
Revenue per Share |
0.97 | 0.97 | 0.95 | 0.97 | |
Operating CF per Share |
0.14 | 0.23 | 0.08 | 0.16 | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.13 | 0.23 | 0.07 | 0.15 | |
Cash per Share |
0.52 | 0.39 | 0.36 | 0.41 | |
Shareholders Equity per Share |
(2.03) | (2.20) | (2.28) | (2.31) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.03) | (2.20) | (2.28) | (2.31) | |
Free Cash Flow |
1.04 | 1.81 | 0.58 | 1.21 | |
Working Capital |
(2.16) | (4.63) | (6.69) | (8.03) | |
Capital Expenditures |
(0.10) | (0.03) | (0.07) | (0.07) | |
Net Current Asset Value |
(65.52) | (67.16) | (68.21) | (68.58) | |
EV/EBIT |
207.47 | 0.00 | 173.71 | 81.46 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
178.89 | 0.00 | 138.04 | 66.58 | |
| Other line items | |||||
Average Receivables |
6.83 | 6.92 | 7.01 | 7.08 | |
Average Payables |
2.52 | 2.54 | 3.02 | 2.38 | |
Average Inventory |
0.59 | 0.49 | 0.54 | 0.53 | |
Average Assets |
62.74 | 62.57 | 62.63 | 63.20 | |
Average Common Equity |
(15.61) | (16.66) | (16.53) | (15.91) |
Columns are period end dates · fundamentals updated 15 Oct 2026